Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial.

@article{Dougados2014SymptomaticEO,
  title={Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial.},
  author={Maxime R Dougados and D{\'e}sir{\'e}e Mfm van der Heijde and Joachim Sieper and J{\"u}rgen Braun and Walter P. Maksymowych and Gustavo Citera and Corinne Miceli-Richard and James Cheng-Chung Wei and Ronald D. Pedersen and Randi Bonin and Mahboob U. Rahman and Isabelle S Logeart and Joseph S Wajdula and Andrew S. Koenig and Bonnie Vlahos and Daniel {\'A}lvarez and Jack F. Bukowski},
  journal={Arthritis & rheumatology},
  year={2014},
  volume={66 8},
  pages={2091-102}
}
OBJECTIVE To assess the efficacy of etanercept in the treatment of early active nonsteroidal antiinflammatory drug (NSAID)-refractory nonradiographic axial spondyloarthritis (SpA). METHODS The study population consisted of patients who met the Assessment of SpondyloArthritis international Society (ASAS) classification criteria for axial SpA but not the modified New York radiographic criteria for ankylosing spondylitis (as assessed by a radiologist at the central trial site), had a symptom… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 9 times over the past 90 days. VIEW TWEETS